Loading…
Loading…
research
SEED Therapeutics, Inc. is a clinical-stage biotechnology company based in King of Prussia, PA, founded in 2019. The company specializes in developing molecular glue degraders aimed at targeting undruggable proteins associated with diseases such as cancer, neurodegeneration, immunology, and virology. SEED utilizes its proprietary RITE3™ platform, which combines structure-based drug design, computational chemistry, and chemical biology to enhance targeted protein degradation. The company's mission focuses on overcoming scientific challenges in discovering molecular glues for therapies that address debilitating diseases. SEED has a pipeline of nine programs, including its lead product, ST-01156, a brain-penetrant RBM39 degrader for Ewing sarcoma and other RBM39-dependent cancers, which is set to enter clinical trials. SEED collaborates with Eisai Co., Ltd. and has partnerships with Eli Lilly and BeyondSpring Pharmaceuticals to support its research and development efforts.
SEED Therapeutics, Inc. is a clinical-stage biotechnology company based in King of Prussia, PA, founded in 2019. The company specializes in developing molecular glue degraders aimed at targeting undruggable proteins associated with diseases such as cancer, neurodegeneration, immunology, and virology. SEED utilizes its proprietary RITE3™ platform, which combines structure-based drug design, computational chemistry, and chemical biology to enhance targeted protein degradation. The company's mission focuses on overcoming scientific challenges in discovering molecular glues for therapies that address debilitating diseases. SEED has a pipeline of nine programs, including its lead product, ST-01156, a brain-penetrant RBM39 degrader for Ewing sarcoma and other RBM39-dependent cancers, which is set to enter clinical trials. SEED collaborates with Eisai Co., Ltd. and has partnerships with Eli Lilly and BeyondSpring Pharmaceuticals to support its research and development efforts.
SEED Therapeutics has been mentioned across 1 podcast.
Represent this company? Request removal or email privacy@pitchcentric.com.
FAQs
If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.
Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.
Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.
A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.
Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.
Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.
You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.
Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.
That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.
